Cited by 162Sirtuins and Resveratrol in MedicineCardiovascular Health and Disease PreventionPhytochemicals and Antioxidant Activities

Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults

Wong, Rachel H.X., Berry, Narelle M., Coates, Alison M., Buckley, Jonathan D., Bryan, Janet, Kunz, Iris, Howe, Peter R.C.·2013·Journal of Hypertension

Abstract

BACKGROUND: We have previously demonstrated acute dose-dependent increases of flow-mediated dilatation (FMD) in the brachial artery after resveratrol consumption in mildly hypertensive, overweight/obese adults. Resveratrol supplementation has also been shown to increase cerebral blood flow acutely, without affecting cognition. OBJECTIVES: To evaluate the effects of chronic resveratrol supplementation on both FMD and cognitive performance. METHOD: Twenty-eight obese but otherwise healthy adults (BMI: 33.3 ± 0.6 kg/m) were randomized to take a single 75 mg capsule of trans-resveratrol (Resvida) or placebo daily for 6 weeks each in a double-blind crossover supplementation trial. Blood pressure, arterial compliance, FMD, and performance on the Stroop Color-Word Test were assessed at the end of each 6-week intervention period while fasted and at least 18 h after taking the last daily capsule. An additional capsule of the same supplement was then taken. FMD assessment was repeated 1 h later. RESULTS: Chronic resveratrol supplementation for 6 weeks was well tolerated and resulted in a 23% increase in FMD compared with placebo (P=0.021, paired t-test). The extent of increase correlated negatively with baseline FMD (r=-0.47, P=0.01). A single dose of resveratrol (75 mg) following chronic resveratrol supplementation resulted in a 35% greater acute FMD response than the equivalent placebo supplementation. These FMD improvements remained significant after adjusting for baseline FMD. Blood pressure, arterial compliance, and all components of the Stroop Color-Word Test were unaffected by chronic resveratrol supplementation. CONCLUSION: Daily resveratrol consumption was well tolerated and has the potential to maintain healthy circulatory function in obese adults.

Integrity signals

Registry

Crossref · 10.1097/hjh.0b013e328362b9d6

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In 2013, the same group conducted a randomized placebo-controlled cross-over study of 28 healthy obese patients (BMI 30-45 kg/m2, aged 40-75 years).

    “In 2013, the same group of authors conducted another randomized placebo-controlled, cross-over study to evaluate the effects of resveratrol at the dose of 75 mg once daily to 28 healthy obese patients (BMI 30–45 kg/m2, aged 40–75 years) [35].”

    From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [35]

  • After 6 weeks of resveratrol 75 mg once daily, FMD increased by more than 23% in healthy obese patients.

    “After 6 weeks of resveratrol administration, FMD increased by more than 23%.”

    From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [35]

  • No adverse effects were reported in that 2013 study.

    “No adverse effects were reported [35].”

    From The Role of Resveratrol Administration in Human Obesity (2021) · cites this paper as [35]

The citation lists haven’t been fetched yet

References 29 · Cited by 162

Authors
Wong, R. H. X., Berry, N. M., Coates, A. M., Buckley, J. D., Bryan, J., Kunz, I., & Howe, P. R. C.
Affiliations
University of South Australia (AU)
Corresponding author
Howe, Peter R.C.
Venue
Journal of Hypertension
Published
2013-09
Volume
31
Issue
9
Pages
1819-1827
ISSN
0263-6352 (ISSN-L)
OpenAlex
W2010342922
Cited by
162
References
29
Citations by year
2026: 4 · 2025: 8 · 2024: 11 · 2023: 8 · 2022: 10 · 2021: 14 · 2020: 11 · 2019: 17 · 2018: 14 · 2017: 18 · 2016: 19 · 2015: 16 · 2014: 10 · 2013: 2
FWCI
7.29
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Hypertension (publishedVersion)
  • PubMed (publishedVersion)
Funders
DSM Nutritional Products
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
  • Health Sciences › Medicine › Biochemistry › Phytochemicals and Antioxidant Activities
Keywords
resveratrol, flow-mediated dilation, brachial artery, obesity, arterial compliance, cognitive performance, Stroop task, blood pressure, circulatory function
MeSH terms
Resveratrol, Adult, Aged, Blood Flow Velocity, Blood Pressure, Brachial Artery, Carotid Arteries, Double-Blind Method, Endothelium, Vascular, Female, Humans, Male, Middle Aged, Obesity, Surveys and Questionnaires, Stilbenes, Vasodilation, Body Mass Index, Postmenopause, Cross-Over Studies, Blood Pressure Monitoring, Ambulatory, Dietary Supplements, Overweight, Stroop Test

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review